University of Utah and Harvard researchers take major step toward first biological test for autism

The test, which uses MRI to measure deviations in brain circuitry, could someday replace the subjective test now used to identify those with the disorder. It could also lead to a better understanding of autism and to better management and treatments of affected individuals.

“This is not yet ready for prime time use in the clinic yet, but the findings are the most promising thus far,” said lead author Nicholas Lange, ScD, Associate Professor of Psychiatry at Harvard Medical School and director of the Neurostatistics Laboratory at McLean. “Indeed, we have new ways to discover more about the biological basis of autism and how to improve the lives of individuals with the disorder,” said senior author Janet Lainhart, MD, Principal Investigator of the research at the University of Utah.

The Harvard-McLean and University of Utah researchers used the test on two groups of subjects. One group consisted of individuals who had previously been diagnosed with high-functioning autism using the standard subjective scoring system. That system is based on assessing patients and questioning their parents about their functionality in a variety of areas including language, social functioning, and behavior. The second group studied was a control group consisting of normally developing individuals.

The subjects were put in an MRI scanner that was programmed to be sensitive to water diffusion along the axons of the brain to measure microscopic features of the brain's circuitry. The Lange-Lainhart test employs Diffusion Tensor Imaging.

“It provides pictures and measurements of the microscopic fiber structures of the brain that enable language, social and emotional functioning, which can reveal deviations that are not found in those without autism,” Lange said.

By measuring six aspects of the brain's circuitry, the test was able to correctly distinguish those who had previously been diagnosed with autism with 94 percent accuracy.

A repeat study using two different sets of subjects showed the same high level of performance.

“The differences picked up on the study correlate with clinical symptoms that are part of the features of autism,” Lainhart said. “There is less directional flow to and from brain regions where there should be more information exchange,” said Lange.

The collaborative research group will further study and develop the test with more findings due out in a year or two. Future studies will look at patients with high-severity autism, younger children, and patients with brain disorders such as developmental language disorders, ADHD and OCD, who do not have autism.

If the test demonstrates further success, it could someday replace the current subjective system of diagnosing autism, which is not biologically based.

It could also someday lead to pinpointing how autism develops. “We can gain a better understanding of how this disorder arises and changes over the lifetime of an individual, and derive more effective treatments,” said Lainhart.

Co-authors included: Molly DuBray, Alyson Froehlich, Brad Wright, P. Thomas Fletcher, all of the University of Utah, Erin Bigler of Brigham Young University, Nagesh Adluru, Alexander Alexander, and Jee Eun Lee of the University of Wisconsin, and Michael Froimowitz and Caitlin Ravichandran at Harvard and McLean.

University of Utah Health Sciences is internationally regarded for its research and clinical expertise in the health sciences. For more information, visit www.healthsciences.utah.edu.

McLean Hospital is the largest psychiatric clinical care, teaching and research facility of Harvard Medical School, an affiliate of Massachusetts General Hospital and a member of Partners HealthCare. For more information about McLean Hospital, visit www.mclean.harvard.edu.